These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 26637871)

  • 1. Bioluminescence Imaging of Adoptively Transferred Lymphocytes During Allogeneic Tumor Rejection.
    Juršėnaitė J; Girkontaitė I; Mauricas M; Eidukevičius R; Šiaurys A; Characiejus D
    Anticancer Res; 2015 Dec; 35(12):6573-6. PubMed ID: 26637871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Accumulation and Clonal Expansion May Not Be Decisive for Rejection of Allogeneic Tumors by CD8
    Juršėnaitė J; Girkontaitė I; Šiaurys A; Mauricas M; Characiejus D
    Anticancer Res; 2018 Aug; 38(8):4481-4484. PubMed ID: 30061213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
    J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of T cell homing by down-regulation of CD62L and the induction of a Th-2 response as a method to prevent acute allograft rejection in mice.
    Stremmel C; Sienel W; Eggeling S; Passlick B; Slavin A
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):362-9. PubMed ID: 16828564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice.
    Lee MK; Huang X; Jarrett BP; Moore DJ; Desai NM; Moh Lian M; Markmann JW; Deng S; Frank A; Singer A; Velidedeoglu E; Caton AJ; Markmann AJ
    Transplantation; 2003 Apr; 75(8):1415-22. PubMed ID: 12717241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
    Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
    Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
    Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
    Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.
    Charo J; Perez C; Buschow C; Jukica A; Czeh M; Blankenstein T
    Eur J Immunol; 2011 Nov; 41(11):3187-97. PubMed ID: 21898380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
    J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity.
    del Rio ML; Kurtz J; Perez-Martinez C; Ghosh A; Perez-Simon JA; Rodriguez-Barbosa JI
    Transplantation; 2011 Nov; 92(10):1085-93. PubMed ID: 21978997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical roles of memory T cells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice.
    Nagata S; Okano S; Yonemitsu Y; Nakagawa K; Tomita Y; Yoshikai Y; Shimada M; Maehara Y; Sueishi K
    Transplantation; 2006 Sep; 82(5):689-98. PubMed ID: 16969294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
    Korbelik M; Dougherty GJ
    Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE; Touhalisky JE; Shu S
    Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.
    Petersen CC; Petersen MS; Agger R; Hokland ME
    J Immunother; 2006; 29(3):241-9. PubMed ID: 16699367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells
    Szyska M; Herda S; Althoff S; Heimann A; Russ J; D'Abundo D; Dang TM; Durieux I; Dörken B; Blankenstein T; Na IK
    Cancer Immunol Res; 2018 Jan; 6(1):110-120. PubMed ID: 29259004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
    Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
    Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.